Julie D. Klapstein
Known title: DirectorCIK: 0001518668
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Claritev Selected by GDIT for WTC Health Program Support. Claritev has been selected by General Dynamics Information Technology (GDIT) to support the World Trade Center Health Program. The financial terms of this agreement were not disclosed. This development adds a notable government-related contract to the company's portfolio, which is relevant context given the stock is currently trading near its 52-week low.
Transaction History
| OMDA | ▲ Buy | Grant | 549 | $0 | 10/5/2026 | View on chart |
| OMDA | ▲ Buy | Grant | 649 | $0 | 7/5/2026 | View on chart |
| OMDA | ▲ Buy | Grant | 10,882 | $0 | 6/16/2026 | View on chart |
| CTEV | ▲ Buy | Grant | 8,977 | $0 | 4/29/2026 | View on chart |
| OMDA | ▲ Buy | Grant | 698 | $0 | 4/5/2026 | View on chart |
| OMDA | ▲ Buy | Grant | 9,736 | $0 | 6/5/2025 | View on chart |
| CTEV | ▲ Buy | Grant | 7,356 | $0 | 4/30/2025 | View on chart |
| CTEV | ▲ Buy | Grant | 172,413 | $0 | 4/24/2024 | View on chart |
| CTEV | ▲ Buy | Grant | 106,382 | $0 | 4/26/2023 | View on chart |
| CTEV | ▲ Buy | Grant | 22,271 | $0 | 4/26/2022 | View on chart |
| CTEV | ▲ Buy | Open Market | 12,000 | $72K | 8/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Omada Health Sets Q3 2026 Earnings Call, Investors Question Valuation
Omada Health will report its third quarter 2026 results on November 5 and host a conference call. Recent commentary highlights the company’s growth but raises concerns about its competitive moat and long‑term price targets. Analysts note a high trailing P/E of 260.2 and a wide target range of $22.00 to $35.00. The upcoming call may clarify how the firm plans to address these valuation questions.
Omada Health Sets Q3 2026 Earnings Call, Investors Question Valuation. Omada Health will report its third quarter 2026 results on November 5 and host a conference call. Recent commentary highlights the company’s growth but raises concerns about its competitive moat and long‑term price targets. Analysts note a high trailing P/E of 260.2 and a wide target range of $22.00 to $35.00. The upcoming call may clarify how the firm plans to address these valuation questions.